[go: up one dir, main page]

HRP940279B1 - IMMUNOGENIC FORMULATION OF OspC ANTIGEN VACCINES FOR THE PREVENTION AND TREATMENT OF LYME DISEASE AND RECOMBINANT METHODS FOR THE PREPARATION OF SUCH ANTIGENS - Google Patents

IMMUNOGENIC FORMULATION OF OspC ANTIGEN VACCINES FOR THE PREVENTION AND TREATMENT OF LYME DISEASE AND RECOMBINANT METHODS FOR THE PREPARATION OF SUCH ANTIGENS

Info

Publication number
HRP940279B1
HRP940279B1 HR940279A HRP940279A HRP940279B1 HR P940279 B1 HRP940279 B1 HR P940279B1 HR 940279 A HR940279 A HR 940279A HR P940279 A HRP940279 A HR P940279A HR P940279 B1 HRP940279 B1 HR P940279B1
Authority
HR
Croatia
Prior art keywords
antigens
prevention
preparation
treatment
recombinant methods
Prior art date
Application number
HR940279A
Other languages
English (en)
Inventor
Livey Ian
Crowe Brian
Dorner Friedrich
Original Assignee
Baxter Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Ag filed Critical Baxter Ag
Publication of HRP940279A2 publication Critical patent/HRP940279A2/hr
Publication of HRP940279B1 publication Critical patent/HRP940279B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HR940279A 1993-04-29 1994-04-29 IMMUNOGENIC FORMULATION OF OspC ANTIGEN VACCINES FOR THE PREVENTION AND TREATMENT OF LYME DISEASE AND RECOMBINANT METHODS FOR THE PREPARATION OF SUCH ANTIGENS HRP940279B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5386393A 1993-04-29 1993-04-29

Publications (2)

Publication Number Publication Date
HRP940279A2 HRP940279A2 (en) 1997-10-31
HRP940279B1 true HRP940279B1 (en) 2000-12-31

Family

ID=21987063

Family Applications (1)

Application Number Title Priority Date Filing Date
HR940279A HRP940279B1 (en) 1993-04-29 1994-04-29 IMMUNOGENIC FORMULATION OF OspC ANTIGEN VACCINES FOR THE PREVENTION AND TREATMENT OF LYME DISEASE AND RECOMBINANT METHODS FOR THE PREPARATION OF SUCH ANTIGENS

Country Status (16)

Country Link
EP (1) EP0701612B1 (fr)
JP (1) JPH08509371A (fr)
AT (1) ATE162550T1 (fr)
AU (1) AU683260B2 (fr)
CA (1) CA2161534A1 (fr)
CZ (1) CZ289212B6 (fr)
DE (1) DE69408135T2 (fr)
DK (1) DK0701612T3 (fr)
ES (1) ES2114687T3 (fr)
FI (1) FI955150L (fr)
HR (1) HRP940279B1 (fr)
HU (1) HU217024B (fr)
NO (1) NO954318L (fr)
PL (1) PL178775B1 (fr)
SK (1) SK279968B6 (fr)
WO (1) WO1994025596A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5915049A (en) * 1992-02-25 1999-06-22 Pfu Limited Binarization system for an image scanner
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
US6716574B2 (en) 1996-05-02 2004-04-06 Dako A/S Osp-C derived peptide fragments
ATE232212T1 (de) * 1996-05-02 2003-02-15 Dako As Verwendung von aus osp-c abgeleiteten peptidefragmenten für diagnostische methoden
US5846946A (en) * 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
AT405940B (de) * 1996-06-21 1999-12-27 Immuno Ag Verfahren zur gewinnung und reinigung von rekombinantem, nicht-lipidiertem osp-protein
DE19629543C2 (de) * 1996-07-22 1999-02-11 Immuno Ag Immunassay zum Nachweis von anti-B. burgdorferi Antikörpern und Verfahren zur Serodiagnose bei Lyme Borreliose, diagnostische Mittel und Testkits zur Durchführung der Verfahren
DE19740735A1 (de) 1997-09-16 1999-03-18 Max Planck Gesellschaft Arzneimittel zur Therapie einer manifesten Lyme-Borreliose
AU5328299A (en) 1998-07-31 2000-02-21 Gundersen Lutheran Medical Foundation, Inc. Uses of the borreliacidal epitope(s) of borrelia burgdorferi outer surface protein c (ospc) as vaccine
EP1683867B1 (fr) 1999-06-18 2014-04-09 Research Foundation Of State University Of New York Groupes de Borrelia burgdorferi et Borrelia afzelii provoquant la maladie de Lyme chez l'homme
DE60131982T2 (de) 2000-08-18 2008-12-11 Brookhaven Science Associates Llc Veränderte borrelia burgdorferi ospa
GB2414667A (en) 2004-06-03 2005-12-07 Isis Innovation Vaccine compositions of N. meningitidis PorA and FetA antigens
AU2006320246A1 (en) * 2005-11-29 2007-06-07 Virginia Commonwealth University Polyvalent chimeric OspC vaccinogen and diagnostic antigen
MX2009004866A (es) * 2006-11-03 2009-05-19 Schering Plough Ltd Vacuna para enfermedad de lyme canina.
CZ301244B6 (cs) * 2007-11-14 2009-12-16 Bioveta, A.S. Univerzální vakcína k lécbe a prevenci Lymeské borreliózy pro humánní a veterinární použití a zpusob její výroby
CZ301548B6 (cs) * 2008-08-20 2010-04-14 Bittner@Libor Univerzální preparát ke zvýšení obranyschopnosti, prevenci, profylaxi a lécbe Lymeské boreliózy pro humánní a veterinární použití, zpusob jeho výroby a použití
WO2025015077A1 (fr) * 2023-07-10 2025-01-16 Dynavax Technologies Corporation Vaccins contre la maladie de lyme contenant un adjuvant et des antigènes des protéines de surface externe a et c de borrelia

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221363B1 (en) * 1991-07-11 2001-04-24 Baxter Aktiengesellschaft Vaccine for the prevention of lyme disease

Also Published As

Publication number Publication date
DE69408135D1 (de) 1998-02-26
HRP940279A2 (en) 1997-10-31
FI955150A0 (fi) 1995-10-27
HU9502002D0 (en) 1995-08-28
CZ283995A3 (en) 1996-03-13
WO1994025596A3 (fr) 1994-12-22
ES2114687T3 (es) 1998-06-01
HUT72923A (en) 1996-06-28
AU683260B2 (en) 1997-11-06
SK134195A3 (en) 1996-05-08
CA2161534A1 (fr) 1994-11-10
DK0701612T3 (da) 1998-09-21
DE69408135T2 (de) 1998-06-10
FI955150L (fi) 1995-12-28
CZ289212B6 (cs) 2001-12-12
AU6722994A (en) 1994-11-21
JPH08509371A (ja) 1996-10-08
EP0701612B1 (fr) 1998-01-21
ATE162550T1 (de) 1998-02-15
HU217024B (hu) 1999-11-29
WO1994025596A2 (fr) 1994-11-10
PL178775B1 (pl) 2000-06-30
SK279968B6 (sk) 1999-06-11
PL311301A1 (en) 1996-02-05
NO954318L (no) 1995-12-29
NO954318D0 (no) 1995-10-27
EP0701612A1 (fr) 1996-03-20

Similar Documents

Publication Publication Date Title
HRP940279B1 (en) IMMUNOGENIC FORMULATION OF OspC ANTIGEN VACCINES FOR THE PREVENTION AND TREATMENT OF LYME DISEASE AND RECOMBINANT METHODS FOR THE PREPARATION OF SUCH ANTIGENS
GB2303854B (en) Helicobacter proteins and vaccines
CA2001328A1 (fr) Antigene de borrellia
DK0598816T3 (da) Osp A-proteiner fra Borrelia Burgdorferi-undergrupper, hvilke proteiner koder for gener og vacciner
ZA883954B (en) Avirulent microbes and uses therefor
EP1630229A3 (fr) Antigènes du melanome
EP0835133A4 (fr) Compositions recombinantes et compositions combinees de virus de la rage et de la variole, et leurs utilisations
PL325373A1 (en) Compounds and methods useful in tuberculosos immunotherapy and diagnostics
NZ331651A (en) BSW17 peptide immunogens for vaccination against and treatment of allergy
DE69533594D1 (de) Präparate und verfahren zum auslösen von ctl-immunität
GR3017778T3 (en) Immunogenic complexes, in particular iscoms.
EP0232798A3 (fr) Mutants de virus pseudorabique, vaccins les contenant, leurs procédés de préparation, ainsi que méthodes pour leur utilisation
AU1800597A (en) Novel methods of vaccination and vaccines therefore comprising a nucleic acid encoding a first epitope and a peptide containing a second epitope
WO2001079259A8 (fr) Complexation d'antigenes proteiques et de proteines de stress par sequence javelot
WO1993014206A3 (fr) Peptides synthetiques destines a un vaccin contre la rubeole
CA2133108A1 (fr) Vaccin a base de toxoide contre pasteurella haemolytica type a-1
WO2002004497A3 (fr) Peptides a antigenes multiples assurant l'immunite contre streptococcus pneumoniae
ES8800052A1 (es) Un procedimiento para preparar una proteina de superficie antigenica de anaplasma marginale
EP1020516A3 (fr) Antigenes vaccinaux de Leptospira pour la prevention de la leptospirose
GB9502899D0 (en) Novel antigen
SE9600646D0 (sv) Vaccin
HUP0002752A2 (hu) Egy szekréciós vektor alkalmazása termékenység-szabályozásra orális vakcinálással
MX9700215A (es) Proteinas y vacunas de helicobacter.
CA2347278A1 (fr) Vaccin a base d'haemophilus somnus attenue

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
PNAN Change of the applicant name, address/residence

Owner name: BAXTER AKTIENGESELLSCHAFT, AT

B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20040406

Year of fee payment: 11

PBON Lapse due to non-payment of renewal fee

Effective date: 20050430